Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 1716 for “"Therapeutics"”.
-
InVivo Therapeutics® Corporation
… allow the spinal cord to heal on its own. InVivo Therapeutics Corporation is a startup founded to commercialize novel science and technology that was developed through a collaborative effort between the Massachusetts Institute of Technology's Langer labs, and the department of Neuroscience at …
-
Assay Development for Tau-directed Therapeutics
… induced tau filaments commonly used to screen therapeutics have also been observed to have structures which are not similar to those found in diseases. We hypothesize that screening therapeutics against tau aggregates with structures similar to those observed in disease may allow for the …
-
RNA Therapeutics for Fibrolamellar Hepatocellular Carcinoma
… chemical modifications. Multiple siRNA therapeutics targeting genes in the liver have been FDA approved. The majority of these use a carbohydrate group, GalNAc, that binds to the asialoglycoprotein receptor (ASGR), allowing targeted delivery to hepatocytes. I hypothesized that ASGR might …
-
ML-assisted therapeutics for neurodegenerative disorders
Submission original under an indefinite embargo labeled 'Open Access'. The submission was exported from vireo on 2023-12-04 without embargo terms
-
Azobenzenes for the development of therapeutics
… a rapidly growing class of targeted cancer therapeutics. Previous reports have shown that ortho-methoxy azobenzenes undergo reductive cleavage in reducing environments, making them ideal candidates for the development of novel GSH-cleavable ADCs, responsive to elevated GSH levels present in …
-
Development of exosome-based anti-cancer therapeutics
… applied to the development of future lung cancer therapeutics.
-
Phosphonium-functionalised gold nanoparticles for mitochondria targeted therapeutics.
The work presented in this thesis demonstrates that triarylphosphoniopropyl-thiosulfate zwitterions and w-thioacetylpropyl(triphenyl)phosphonium salts can be used to prepare cationic, water-soluble gold nanoparticles with mean core sizes in the range of 2.5-5 nm. Phosphonium-functionalised gold …
-
Improving Bacterial Therapeutics and Diagnostics through Synthetic Biology
… and the pharmacokinetic profile of bacterial therapeutics. Second, we engineered Escherichia coli to sense extracellular proteins. A cell-surface sensor is crucial to enable broad diagnostic and therapeutic applications of bacteria; however, Gram-negative bacteria such as E. coli can only …
-
IDENTIFYING AND EXPLOITING SYNTHETIC LETHALITY FOR CANCER THERAPEUTICS
Synthetic Lethality (SL) is considered a promising approach for the development of personalized treatments. However, SL interactions in humans remain largely unknown and there is a need to discover more such pairs, especially those that are clinically actionable, and to develop tools that can …
-
Investigation of novel topical therapeutics for chronic rhinosinusitis
Chronic rhinosinusitis (CRS) is a common condition that arises from interactions between anatomical factors, perturbations of the local microbial community including the formation of bacterial biofilms, and dysfunction of the host immune responses. First-line treatments are saline nasal irrigation …
-
Designed Bond Cleavage Reactions for Next-Generation Therapeutics
… being a significant proportion of small-molecule therapeutics. Chemical moieties, such as the ,-unsaturated system in acrylamides, make it challenging to design a prodrug approach. Here, we explore the use of caged cyanoacrylates, which are designed to remain inert until activated by a rapid C–C …
-
Tumor-penetrating delivery of small interfering RNA therapeutics
… challenge, as small interfering RNA (siRNA) therapeutics must overcome clearance mechanisms and penetrate into tumor tissues to access cancer cells. This thesis sought to develop nanotechnology-based platforms to rapidly discover and validate cancer targets in vivo. First, we developed …
-
Mitochondrial Uncouplers: Development as Therapeutics for Metabolic Diseases
… need for effective weight management therapeutics. Obesity presents clinically diverse phenotypes that increase a person's susceptibility to comorbidities that commonly result in deteriorated health (cardiovascular disease, diabetes mellitus, hypertension, etc). A comorbidity of …
-
Development of Novel Small-Molecule Therapeutics for Multiple Sclerosis
Protein arginine deiminase (PAD) activity is upregulated in MS and the overactive enzymes convert peptidyl arginine on myelin structural proteins to neutral citrulline variants. Hypercitrullination disrupts key ionic interactions between myelin proteins and lipid bilayers that are necessary to …
-
Nuclear Factor Kappa B Pathway and human cancer therapeutics
Cancer is one of the major causes of morbidity in the world. Although the overall survival of cancer has been significantly improved by chemotherapy in the last three decades, the success of cancer chemotherapy is still severely limited by the lack of selectivity of anti-cancer drugs to malignant …
-
De novo design of protein binders as functional therapeutics
… designed minibinders as novel functional therapeutics: in Chapter 2, I report the design of minibinder antagonists as immune modulator for cytokine storm; in Chapter 3, I report the design of endocytosis ligands for target degradation and signaling amplification. Overall, the minibinder is …
-
Bst2 Isoforms: Distribution and Potential Use In Cancer Therapeutics
<p>Identifying a cancer-specific cellular target is one of the key factors that can pave a “bench to the bedside” path of a target therapy. Bone marrow stromal cell antigen 2 (BST2) is a raft-associated type II transmembrane protein with an unusual topology. Analyses showed a variable degree of …
-
Intranasal delivery of therapeutics targeted to CSF and Brain
… fluid barrier limit the systemic delivery of therapeutics to the brain and cerebrospinal fluid (CSF) respectively. Therapeutic agents targeting CNS are currently being administered by invasive routes which are not patient compliant and do not allow frequent administration. Intranasal delivery …
Page 1 of 86